The DOI matches its Crossref record.
Efficacy of Curcuma longa in treatment of postprandial distress syndrome: An open-label randomized-controlled trial
Abstract
Background: Proton pump inhibitors are effective for functional dyspepsia but ineffective in relieving postprandial distress syndrome. Curcuma longa might be effective for postprandial distress syndrome. The objective of this study was to compare the efficacy of Curcuma longa and simethicone for postprandial distress syndrome in an open-label randomized-controlled trial. Methods: This trial was conducted between July 2018 and February 2019. In total, 78 patients were randomly assigned to receive 4 weeks of treatment with 750 or 1,500 mg oral Curcuma longa per day or 240 mg simethicone per day. The patients assessed their symptoms using the dyspepsia Global Overall Symptom scale at baseline, week 2, and week 4. After stopping medication for 2 weeks, the patients assessed recurrent symptoms and day of recurrence by themselves at the end of week 6. Results: In total, 78 patients underwent randomization (27 in 750 mg Curcuma longa , 26 in 1500 mg Curcuma longa , and 25 in simethicone groups). After 2 weeks, there were no significant differences in all mean changes of symptoms scores (95%CI) of postprandial distress syndrome [-4.1 (-4.5, -2.6) vs -4.3 (-5.2, -3.3) vs -4.2 (-4.8, -3.5), P=0.954]. Over a period of 4 weeks, the reduction in mean scores was greater among participants receiving simethicone (although not statistically significant) compared with two intervention groups [-4.6 (-5.7, -3.6) vs -5.4 (-6.6, -4.1) vs -6.2 (-7.2, -5.2), P=0.122]. The rate of recurrence was significantly lower in simethicone than the two Curcuma longa groups (42.9 vs 45.5 vs 13.6%, P=0.047). There was no serious adverse event reported in all three groups. Conclusions: Curcuma longa had a similar effect on treatment outcomes to simethicone after 2 and 4 weeks, but the recurrence rate of symptoms was significantly higher without serious adverse events. Registration: Registered with the Thai Clinical Trials Registry on 31 January 2018; TCTR20180131001 .
Overview
The claims and statistics of this paper haven’t been checked yet.
Run the check — free, no account needed. It reads the open-access text and checks the sources it cites.
Integrity signals
Registry
Cites
Statistics
Verification
Claims the paper makes
The claims and statistics of this paper haven’t been checked yet.
Run the check — free, no account needed. It reads the open-access text and checks the sources it cites.
Claims other papers make about this one
Each is checked against this paper’s own text: does it say what the citing paper says it does?
In the citing paper
“Similarly, in a comparison of two dosages of curcumin extract and simethicone, there were significant changes in composite scores of a Global Overall Symptom scale from baseline to 4 weeks of treatment for all groups (within-group differences: p < 0.001 for all groups) (Sawangroj et al., 2019); however, the differences of differences between the curcumin extract and simethicone groups were not”
From A systematic review of the efficacy and safety of turmeric in the treatment of digestive disorders (2024) · cites this paper as Sawangroj et al., 2019
Self-check
Percentages, sums and reported differences re-computed from the paper’s own numbers.
The self-check needs the paper’s full text.
Citations
Cites
No references could be resolved yet.
Research works printed but not linked: 29
- A Ford, 2015, Global prevalence of, and risk factors for, uninvestigated dyspepsia: a meta-analysis., Gut., 64, 1049-1057, 10.1136/gutjnl-2014-307843 · DOI
- A Ford, 2007, Initial poor quality of life and new onset of dyspepsia: results from a longitudinal 10-year follow-up study., Gut., 56, 321-327, 10.1136/gut.2006.099846 · DOI
- S van Zanten, 2011, Randomised clinical trial: the burden of illness of uninvestigated dyspepsia before and after treatment with esomeprazole--results from the STARS II study., Aliment Pharmacol Ther., 34, 714-723, 10.1111/j.1365-2036.2011.04789.x · DOI
- B Lacy, 2013, Functional dyspepsia: the economic impact to patients., Aliment Pharmacol Ther., 38, 170-177, 10.1111/apt.12355 · DOI · Paper page
- V Stanghellini, 2016, Gastroduodenal Disorders., Gastroenterology., 150, 1380-1392, 10.1053/j.gastro.2016.02.011 · DOI · Paper page
- G Bertoni, 1992, Randomized placebo-controlled trial of oral liquid simethicone prior to upper gastrointestinal endoscopy., Endoscopy., 24, 268-270, 10.1055/s-2007-1010479 · DOI
- R Meier, 2007, Review of the therapeutic use of simethicone in gastroenterology., Schweiz Zschr GanzheitsMedizin., 19, 380-387, 10.1159/000286002 · DOI
- L Brecević, 1994, Mechanism of antifoaming action of simethicone., J Appl Toxicol., 14, 207-211, 10.1002/jat.2550140311 · DOI
- J Wess, 1978, Etiology and management of gastrointestinal gas., GEN., 32, 259-263
- M Van Ness, 1985, Flatulence: pathophysiology and treatment., Am Fam Physician., 31, 198-208
- I Danhof, 1974, Accelerated transit of intestinal gas with simethicone., Obstet Gynecol., 44, 148-154
- J Bergmann, 1989, Use of dimethicone to reduce the fall in gastric potential difference induced by bile salts., Eur J Clin Pharmacol., 36, 379-381, 10.1007/bf00558299 · DOI
- G Holtmann, 1999, Randomised double-blind comparison of simethicone with cisapride in functional dyspepsia., Aliment Pharmacol Ther., 13, 1459-1465, 10.1046/j.1365-2036.1999.00644.x · DOI
- G Holtmann, 2002, A randomized placebo-controlled trial of simethicone and cisapride for the treatment of patients with functional dyspepsia., Aliment Pharmacol Ther., 16, 1641-1648, 10.1046/j.1365-2036.2002.01322.x · DOI
- M Lecuyer, 2009, Efficacy of an activated charcoal-simethicone combination in dyspeptic syndrome: Results of a placebo-controlled prospective study in general practice., Gastroenterol Clin Biol., 33, 478-84, 10.1016/j.gcb.2008.09.021 · DOI
- B Coffin, 2011, Efficacy of a simethicone, activated charcoal and magnesium oxide combination (Carbosymag®) in functional dyspepsia: Results of a general practice-based randomized trial., Clin Res Hepatol Gastroenterol., 35, 494-9, 10.1016/j.clinre.2011.02.009 · DOI
- V Thamlikitkul, 1989, Randomized double blind study of Curcuma domestica Val. for dyspepsia., J Med Assoc Thai., 72, 613-20
- L Liu, 2013, Curcumin ameliorates dextran sulfate sodium-induced experimental colitis by blocking STAT3 signaling pathway., Int Immunopharmacol., 17, 314-20, 10.1016/j.intimp.2013.06.020 · DOI
- Z Zeng, 2013, Curcumin improves TNBS-induced colitis in rats by inhibiting IL-27 expression via the TLR4/NF-κB signaling pathway., Planta Med., 79, 102-9, 10.1055/s-0032-1328057 · DOI
- T Ali, 2012, Curcumin and inflammatory bowel disease: biological mechanisms and clinical implication., Digestion., 85, 249-255, 10.1159/000336720 · DOI
- T Patcharatrakul, 2016, Chili Peppers, Curcumins, and Prebiotics in Gastrointestinal Health and Disease., Curr Gastroenterol Rep., 18, 19, 10.1007/s11894-016-0494-0 · DOI · Paper page
- S Sirijarugul, 2008, Comparative efficacy of curcuma longa and ranitidine in patients with uninvestigated dyspepsia., Proceedings of The Eighth Joint Sminar Innovative Research in Natural Products for Sustainable Development., 261-262
- A Khonche, 2016, Adjunctive Therapy with Curcumin for Peptic Ulcer: a Randomized Controlled Trial., Drug Res (Stuttg)., 66, 444-8, 10.1055/s-0042-109394 · DOI · Paper page
- S Veldhuyzen van Zanten, 2006, Validation of a 7-point Global Overall Symptom scale to measure the severity of dyspepsia symptoms in clinical trials., Aliment Pharmacol Ther., 23, 521-9, 10.1111/j.1365-2036.2006.02774.x · DOI
- S Chow, 2008, Sample Size Calculations in Clinical Research, 2nd edition
- N Sawangroj, 2019, CurcumaUnderlyingData and CurcumaCONSORTchecklist., Figshare.
- B Chumworathayi, 2019, CurcumaDataDictionary., Figshare.
- R Bernal-Reyes, 2013, [Prevalence of gastrointestinal symptoms in overweight and obese subjects: an epidemiologic study on a Mexican population]., Rev Gastroenterol Mex., 78, 28-34, 10.1016/j.rgmx.2012.10.006 · DOI
- O Trujillo-Benavides, 2010, [Influence of obesity on dyspepsia symptoms]., Rev Gastroenterol Mex., 75, 247-52
Cited by
A systematic review of the efficacy and safety of turmeric in the treatment of digestive disorders
Thavorn, K., Wolfe, D., Faust, L., Shorr, R., Akkawi, M., Isaranuwatchai, W., Klinger, C., Chai‐Adisaksopa, C., Tanvejsilp, P., Nochaiwong, S., et al. (2024) · Phytotherapy Research · doi:10.1002/ptr.8189 · Cited by 11
Metadata
- Authors
- Sawangroj, N., Budkaew, J., & Chumworathayi, B.
- Venue
- F1000Research
- Publisher
- F1000 Research Ltd
- Published
- 2019-10-30
- Volume
- 8
- Pages
- 1827
- ISSN
- 2046-1402
- Cited by
- 3
- References
- 0
- Language
- en
- Licence
- creativecommons.org/licenses/by/4.0/ (tdm)
- Funders
- Khon Kaen University (KE61020)
About these checks
Registry, retraction, Cites and statistics results are computed, not judged, with one exception: a printed reference that no index lists is read once by a model before it counts as a citation error. Claims are extracted by a model and kept only when their quote appears verbatim in the text; each cited source is then checked, with a model’s help, for whether it says what the claim relies on. Those verdicts can be wrong — read the claim’s quote and the cited source before relying on one.
Statistics and arithmetic are recomputed, not judged.
Confidence bands are shown only for fields calibrated on our annotated test set. None is calibrated yet, so no band is shown.
What counts as a claim ›How we measure confidence ›How we check this ›
Are you an author, or do you see a problem with this page? Request a review
Data sources
Bibliographic data: Semantic Scholar, OpenAlex, Crossref.
Contains information from the Semantic Scholar Academic Graph Datasets, made available under the ODC Attribution License (ODC-BY 1.0).
Semantic Scholar’s data is described in: Kinney, R., et al. (2023). The Semantic Scholar Open Data Platform. arXiv:2301.10140.
